U.S. flag

An official website of the United States government

NM_002449.5(MSX2):c.2T>C (p.Met1Thr) AND Cranium bifidum occultum

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
May 26, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003760429.2

Allele description [Variation Report for NM_002449.5(MSX2):c.2T>C (p.Met1Thr)]

NM_002449.5(MSX2):c.2T>C (p.Met1Thr)

Gene:
MSX2:msh homeobox 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
5q35.2
Genomic location:
Preferred name:
NM_002449.5(MSX2):c.2T>C (p.Met1Thr)
HGVS:
  • NC_000005.10:g.174724661T>C
  • NG_008124.1:g.5090T>C
  • NM_001363626.2:c.2T>C
  • NM_002449.5:c.2T>CMANE SELECT
  • NP_001350555.1:p.Met1Thr
  • NP_002440.2:p.Met1Thr
  • NC_000005.9:g.174151664T>C
Protein change:
M1T
Molecular consequence:
  • NM_001363626.2:c.2T>C - initiator_codon_variant - [Sequence Ontology: SO:0001582]
  • NM_002449.5:c.2T>C - initiator_codon_variant - [Sequence Ontology: SO:0001582]
  • NM_001363626.2:c.2T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_002449.5:c.2T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cranium bifidum occultum
Synonyms:
CRANIUM BIFIDUM, HEREDITARY; Enlarged parietal foramina; CATLIN MARKS
Identifiers:
MedGen: C1868598; Human Phenotype Ontology: HP:0004423

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV004536942Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Uncertain significance
(May 26, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004536942.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. This variant has not been reported in the literature in individuals affected with MSX2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects the initiator methionine of the MSX2 mRNA. The next in-frame methionine is located at codon 53.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024